

## Array testing for multiplex assays

PEIJIE HOU

*Statistical and Quantitative Sciences, Takeda Pharmaceutical Inc., 300 Massachusetts Avenue,  
Cambridge, MA 02139, USA*

JOSHUA M. TEBBS\*, DEWEI WANG

*Department of Statistics, University of South Carolina, 1523 Greene St, Columbia, SC 29208, USA*  
tebbs@stat.sc.edu

CHRISTOPHER S. MCMAHAN

*School of Mathematical and Statistical Sciences, Clemson University, O-110 Martin Hall, Box 340975,  
Clemson, SC 29634, USA*

CHRISTOPHER R. BILDER

*Department of Statistics, University of Nebraska-Lincoln, 340 Hardin Hall North, Lincoln,  
NE 68583, USA*

### SUMMARY

Group testing involves pooling individual specimens (e.g., blood, urine, swabs, etc.) and testing the pools for the presence of disease. When the proportion of diseased individuals is small, group testing can greatly reduce the number of tests needed to screen a population. Statistical research in group testing has traditionally focused on applications for a single disease. However, blood service organizations and large-scale disease surveillance programs are increasingly moving towards the use of multiplex assays, which measure multiple disease biomarkers at once. Tebbs *and others* (2013, Two-stage hierarchical group testing for multiple infections with application to the Infertility Prevention Project. *Biometrics* **69**, 1064–1073) and Hou *and others* (2017, Hierarchical group testing for multiple infections. *Biometrics* **73**, 656–665) were the first to examine hierarchical group testing case identification procedures for multiple diseases. In this article, we propose new non-hierarchical procedures which utilize two-dimensional arrays. We derive closed-form expressions for the expected number of tests per individual and classification accuracy probabilities and show that array testing can be more efficient than hierarchical procedures when screening individuals for multiple diseases at once. We illustrate the potential of using array testing in the detection of chlamydia and gonorrhea for a statewide screening program in Iowa. Finally, we describe an R/Shiny application that will help practitioners identify the best multiple-disease case identification algorithm.

*Keywords:* Case identification; Group testing; Infertility prevention project; Matrix pooling; Pooled testing; Screening.

\*To whom correspondence should be addressed.

## 1. INTRODUCTION

When screening a population for low-prevalence diseases, testing specimens in pools can be far more cost efficient than testing specimens individually. Individuals in pools that test negatively can be classified as negative, and individuals in pools that test positively can be retested to determine which ones are positive. Testing pooled specimens, which is known as group testing, has a long history dating back to [Dorfman \(1943\)](#), who proposed it to screen United States military recruits for syphilis. Today, group testing is routinely used to screen blood and plasma donations for HIV, HBV, and HCV in the United States and in other developed nations ([Mine and others, 2003](#); [Seed and others, 2005](#); [Vansteelandt and others, 2005](#); [Schmidt and others, 2010](#); [O'Brien and others, 2012](#); [Stramer and others, 2013](#)). Group testing also arises in screening and surveillance applications for other diseases, including West Nile virus ([Busch and others, 2005](#)), chlamydia and gonorrhea ([Lewis and others, 2012](#)), malaria ([Wang and others, 2014](#)), influenza ([Edouard and others, 2015](#)), and Zika virus ([Saá and others, 2018](#)).

There is a substantial literature on group testing case identification algorithms for a single disease, where the goal is to classify each individual as positive or negative. Such algorithms are generally described as being “hierarchical” or “non-hierarchical” in nature. A hierarchical algorithm uses master pools that are non-overlapping, and positive pools are resolved in stages by splitting each one into smaller non-overlapping subpools. Dorfman’s original proposal was to accomplish this in two stages; i.e., master pools are tested in the first stage and individuals (from positive pools) are tested in the second. When the disease prevalence is low, increasing the number of stages can further reduce the number of tests needed. For example, [Pilcher and others \(2005\)](#) use a three-stage algorithm for HIV testing in North Carolina with a master pool of size 90, nine second-stage subpools of size 10, and individual testing in the third stage. [Sherlock and others \(2007\)](#) describe how variations of this three-stage testing algorithm have been implemented in public health laboratories throughout the United States.

Array testing, also known as matrix pooling, is the most common type of non-hierarchical case identification algorithm. In (two-dimensional) array testing procedures, individual specimens are assigned to an array consisting of rows and columns. Row and column master pools are tested in the first stage, and individuals not classified as negative after the first stage are retested in the second. [Phatarfod and Sudbury \(1994\)](#) introduced array testing for disease screening purposes in the absence of testing error. [Kim and others \(2007\)](#) and [Westreich and others \(2008\)](#) offered comparisons of array testing and hierarchical algorithms for single diseases while allowing for imperfect assays. In other single-disease settings, [Hudgens and Kim \(2011\)](#) determined optimal configurations for square arrays, [McMahan and others \(2012\)](#) acknowledged individual covariate information, and [Lendle and others \(2012\)](#) accounted for correlated responses. [Kim and Hudgens \(2009\)](#) examined array testing in higher dimensions where, geometrically, one can envision that rows and columns are tested across multiple planes or hyperplanes. [Martin and others \(2013\)](#) implemented a three-dimensional version of this algorithm for HIV testing in New Jersey.

In this article, we extend the use of array testing to test for multiple diseases simultaneously. Our work is motivated by the development and increased use of “multiplex assays,” which detect multiple pathogens in a single application. These assays reduce the workload involved in screening a population for multiple diseases when compared with using singleplex (or one-disease) assays for each disease separately. Previous research merging group testing with multiplex assays has considered only hierarchical case identification algorithms. [Tebbs and others \(2013\)](#) characterized the performance of a two-stage algorithm for two diseases, motivated by current chlamydia and gonorrhea testing practices in Iowa. More recently, [Hou and others \(2017\)](#) developed a Markov chain framework to propose higher-stage hierarchical algorithms for multiple diseases. Here, the focus of our article is on group testing with multiplex assays carried out by using two-dimensional arrays. We demonstrate that this non-hierarchical design can be more efficient than hierarchical algorithms, a practically important finding for laboratories and high-volume testing centers that screen individuals for multiple diseases at once.

In Section 2, we define notation and restate the assumptions in Hou and others (2017), which are also used in this article. In Section 3, we describe how to derive closed-form expressions for the expected number of tests per individual and classification accuracy probabilities for two diseases in two-dimensional arrays. These expressions are complex when allowing for testing error, so we make extensive use of the supplementary material available at Biostatistics online. In Section 4, we provide a thorough comparison of array testing and the hierarchical algorithms in Tebbs and others (2013) and Hou and others (2017). In Section 5, we illustrate the potential benefit of using array testing when screening Iowa residents for chlamydia and gonorrhea simultaneously. In Section 6, we provide a summary discussion and describe our online resources that will help practitioners identify the best multiplex algorithm.

2. NOTATION AND ASSUMPTIONS

Suppose individual specimens (e.g., blood, urine, swabs, etc.) are randomly assigned to the cells of an  $n \times n$  array, where  $n \geq 2$ . In this article, we consider square arrays for simplicity, although generalizing our derivations for rectangular arrays is possible. To simplify the exposition, we assume the number of diseases is  $K = 2$ ; see Section 6 for a discussion on using array testing for more than two diseases. Let  $\mathcal{I}_{ij}$  denote the individual assigned to the  $(i, j)$  cell, for  $i = 1, 2, \dots, n$  and  $j = 1, 2, \dots, n$ . In the first stage, rows are tested producing  $\mathbf{R}_1, \mathbf{R}_2, \dots, \mathbf{R}_n$ , where  $\mathbf{R}_i = (R_{i1}, R_{i2})'$  and  $R_{ik} = 1$  ( $R_{ik} = 0$ ) if the  $i$ th row tests positively (negatively) for the  $k$ th disease,  $k = 1, 2$ . Columns are also tested in the first stage producing  $\mathbf{C}_1, \mathbf{C}_2, \dots, \mathbf{C}_n$ , where  $\mathbf{C}_j = (C_{j1}, C_{j2})'$  and  $C_{jk} = 1$  ( $C_{jk} = 0$ ) if the  $j$ th column tests positively (negatively)




Fig. 1. A  $5 \times 5$  array for  $K = 2$  diseases. Row and column master pool testing responses  $\mathbf{R}_1, \mathbf{R}_2, \dots, \mathbf{R}_5$  and  $\mathbf{C}_1, \mathbf{C}_2, \dots, \mathbf{C}_5$  are observed in the first stage. The second stage involves retesting individuals  $\mathcal{I}_{ij} \in \mathcal{M}_+$  as described in Section 2.

for the  $k$ th disease. Figure 1 illustrates this notation for  $n = 5$ ; i.e., a  $5 \times 5$  array. It is important to emphasize that  $\mathbf{R}_1, \mathbf{R}_2, \dots, \mathbf{R}_n$  and  $\mathbf{C}_1, \mathbf{C}_2, \dots, \mathbf{C}_n$  are the testing responses in the first stage; they could be incorrect because of inherent assay error.

In the second stage, individual testing is used for those individuals not declared to be negative after the first stage. If an assay is perfect, this collection of individuals is easy to determine, that is, one need only to examine the intersections of positive rows and columns. Otherwise, ambiguities may arise. For example, if the first row tests positively for the first disease (i.e.,  $R_{11} = 1$ ) but all columns test negatively for the first disease (i.e.,  $C_{11} = C_{21} = \dots = C_{n1} = 0$ ), we assume this is an ambiguity caused by assay error. To resolve this, we adopt the strategy in [Kim and others \(2007\)](#) and retest all individuals in the first row. Following this convention for each disease separately (and allowing for the analogous case when all rows test negatively), let  $\mathcal{M}_+$  denote the collection who are tested individually in the second stage. Mathematically, we can express  $\mathcal{M}_+ = \{\mathcal{I}_{ij} : T_{ij1}^{(\text{AT})} + T_{ij2}^{(\text{AT})} \geq 1\}$ , where

$$T_{ijk}^{(\text{AT})} = I(R_{ik} = 1, C_{jk} = 1) + I\left(R_{ik} = 1, \sum_{j=1}^n C_{jk} = 0\right) + I\left(\sum_{i=1}^n R_{ik} = 0, C_{jk} = 1\right),$$

$k = 1, 2$ , and  $I(\cdot)$  is the indicator function. Individuals in the complement set  $\mathcal{M}_- = \mathcal{M}_+^c$  are not tested in the second stage and are declared to be negative for both diseases.

We now list five assumptions that are made for the remainder of this article. These assumptions are analogous to those in [Hou and others \(2017\)](#) for hierarchical algorithms and are used to derive operating characteristics in closed form.

**ASSUMPTION 1** A discriminating multiplex assay is used to test both rows and columns in the first stage. Briefly, a multiplex assay is said to *discriminate* if upon application it provides a diagnosis for each disease separately. For example, a discriminating multiplex assay applied to the first row in Figure 1 produces both  $R_{11}$  and  $R_{12}$ . This same assay is also used to test individuals  $\mathcal{I}_{ij} \in \mathcal{M}_+$  in the second stage.

**ASSUMPTION 2** Let  $\tilde{\mathbf{Y}}_{ij} = (\tilde{Y}_{ij1}, \tilde{Y}_{ij2})'$  denote the true disease status of individual  $\mathcal{I}_{ij}$ . The  $\tilde{\mathbf{Y}}_{ij}$ 's are independent and identically distributed random vectors with probability mass function  $\text{pr}(\tilde{Y}_{ij1} = \tilde{y}_1, \tilde{Y}_{ij2} = \tilde{y}_2) = p_{00}^{(1-\tilde{y}_1)(1-\tilde{y}_2)} p_{10}^{\tilde{y}_1(1-\tilde{y}_2)} p_{01}^{(1-\tilde{y}_1)\tilde{y}_2} p_{11}^{\tilde{y}_1\tilde{y}_2}$ , where  $\tilde{y}_1, \tilde{y}_2 \in \{0, 1\}$  and  $p_{00} + p_{10} + p_{01} + p_{11} = 1$ .

**ASSUMPTION 3** Let  $S_{e:k}^{(n)}$  and  $S_{p:k}^{(n)}$  denote the multiplex assay sensitivity and specificity for testing row and column master pools of size  $n$ , respectively, for the  $k$ th disease ( $k = 1, 2$ ). Let  $S_{e:k}^{(1)}$  and  $S_{p:k}^{(1)}$  denote the same multiplex assay accuracy probabilities for individual testing. We assume  $S_{e:k}^{(n)}, S_{p:k}^{(n)}, S_{e:k}^{(1)}$ , and  $S_{p:k}^{(1)}$  are known.

**ASSUMPTION 4** We assume  $S_{e:k}^{(n)}$  and  $S_{p:k}^{(n)}$  for one disease do not depend on the true status of the other disease. The same assumption is made for  $S_{e:k}^{(1)}$  and  $S_{p:k}^{(1)}$ .

**ASSUMPTION 5** Testing responses on rows, columns, and individuals are mutually independent, conditional on the true disease statuses of all individuals.

Several comments are in order. First, the widespread availability of discriminating multiplex assays for disease detection is discussed in [Tebbs and others \(2013\)](#) and [Hou and others \(2017\)](#). Multiplex assays best described as non-discriminating (i.e., assays that do not differentiate between diseases) are not considered in this article. In Assumption 3, we allow the sensitivity and specificity of the multiplex assay to be pool-size dependent as in [Hou and others \(2017\)](#). Pilot data on assay performance, which are typically available in the product literature published by manufacturers, can be used to elicit values

for these accuracy probabilities; see also Section 6. Assumption 4 requires that an assay have adequate discriminating power to differentiate between diseases and that there is no interference in detection; see, for example, [Ellington and others \(2010\)](#) for a discussion of this issue with antibody-based multiplex assays. Finally, the conditional independence requirement in Assumption 5 is also common in the case identification literature for single diseases. This assumption means that misclassification can arise only because of errors in test implementation or other factors not related to true disease status.

### 3. OPERATING CHARACTERISTICS

We describe how to derive the expected number of tests per individual and classification accuracy probabilities for array testing with  $K = 2$  diseases. The derivations are formidable when allowing for imperfect assays, so we highlight the salient starting points herein and relegate specifics to the [supplementary material](#) available at *Biostatistics* online. We also describe a modified version of the two-stage algorithm in Section 2 that includes a preliminary test on the entire array.

#### 3.1. Efficiency

Henceforth, we denote the two-stage algorithm in Section 2 by AT. The first stage of AT uses  $2n$  tests for the rows and columns. Second-stage individual testing is used when the event  $\{T_{ij1}^{(AT)} + T_{ij2}^{(AT)} \geq 1\}$  occurs. Therefore, the expected number of tests per individual, or *efficiency*, for AT is given by

$$\text{EFF(AT)} = \frac{1}{n^2} \left\{ 2n + n^2 \text{pr}(T_{ij1}^{(AT)} + T_{ij2}^{(AT)} \geq 1) \right\},$$

where  $\text{pr}(T_{ij1}^{(AT)} + T_{ij2}^{(AT)} \geq 1) = \text{pr}(T_{ij1}^{(AT)} = 1) + \text{pr}(T_{ij2}^{(AT)} = 1) - \text{pr}(T_{ij1}^{(AT)} = 1, T_{ij2}^{(AT)} = 1)$ . Calculating the marginal probability  $\text{pr}(T_{ij1}^{(AT)} = 1)$  is straightforward. By considering only the first disease, one can take Equation (9) in [Kim and others \(2007\)](#) and replace  $S_e (S_p)$  with  $S_{e:1}^{(n)} (S_{p:1}^{(n)})$  and  $q$  with  $\bar{\pi}_1 = 1 - \pi_1$ , where  $\pi_1 = p_{10} + p_{11}$  is the marginal prevalence of the first disease. Calculating  $\text{pr}(T_{ij2}^{(AT)} = 1)$  is done similarly for the second disease by using  $S_{e:2}^{(n)}, S_{p:2}^{(n)}$ , and  $\bar{\pi}_2 = 1 - \pi_2$ , where  $\pi_2 = p_{01} + p_{11}$ .

Calculating the joint probability  $\text{pr}(T_{ij1}^{(AT)} = 1, T_{ij2}^{(AT)} = 1)$  is difficult. Because array testing is generally preferred for low-prevalence diseases, one might initially think to treat this probability as being negligible or at least to approximate it under the assumption of no testing error, thereby creating a simple approximation for  $\text{EFF(AT)}$ . We concluded that both strategies would be unwise. Not only does this lack verisimilitude (as few assays are perfect), but we have found that this probability can be non-trivial even when the diseases are rare. By exploiting the symmetry between rows and columns of the array, we can express  $\text{pr}(T_{ij1}^{(AT)} = 1, T_{ij2}^{(AT)} = 1)$  as the sum

$$\begin{aligned} & \text{pr}(\mathbf{R}'_i = (1, 1), \mathbf{C}'_j = (1, 1)) + 2 \sum_{k=1}^n \text{pr} \left( \mathbf{R}'_i = (1, 1), C_{jk} = 1, \sum_{j'=1}^n C_{j'k} = 0 \right) \\ & + 2 \text{pr} \left( \mathbf{R}'_i = (1, 1), \sum_{j'=1}^n C_{j'1} = 0, \sum_{j'=1}^n C_{j'2} = 0 \right) \\ & + 2 \text{pr} \left( R_{i1} = 1, \sum_{j'=1}^n C_{j'1} = 0, C_{j2} = 1, \sum_{i'=1}^n R_{i'2} = 0 \right). \end{aligned}$$

In the [supplementary material](#) available at *Biostatistics* online, we derive each of these probabilities. The derivations themselves are similar in spirit to those in the array testing literature for single diseases; see, e.g., [Kim and others \(2007\)](#). However, in the presence of testing error, these derivations are substantially more challenging and provide different answers when compared with the single-disease setting (e.g., when treating individuals as “disease free” or not).

### 3.2. Classification accuracy

As in [Tebbs and others \(2013\)](#) and [Hou and others \(2017\)](#), we define the pooling sensitivity  $\text{PS}_{e:k}$  as the probability an individual is classified as positive for the  $k$ th disease,  $k = 1, 2$ , given that the individual is truly positive for the  $k$ th disease. In two-dimensional array testing,

$$\text{PS}_{e:k} = \text{pr}(Y_{ijk} = 1, T_{ij1}^{(\text{AT})} + T_{ij2}^{(\text{AT})} \geq 1 | \tilde{Y}_{ijk} = 1),$$

where  $\tilde{Y}_{ijk}$  denotes the true (binary) status of individual  $\mathcal{I}_{ij}$  for disease  $k$  and  $Y_{ijk}$  denotes the corresponding individual testing response. The pooling specificity  $\text{PS}_{p:k}$  is defined analogously for truly negative individuals being classified negatively; i.e.,

$$\text{PS}_{p:k} = 1 - \text{pr}(Y_{ijk} = 1, T_{ij1}^{(\text{AT})} + T_{ij2}^{(\text{AT})} \geq 1 | \tilde{Y}_{ijk} = 0).$$

Using the inclusion-exclusion rule for conditional probabilities, we can write the pooling sensitivity  $\text{PS}_{e:k}$  as

$$\begin{aligned} \text{pr}(Y_{ijk} = 1, T_{ijk}^{(\text{AT})} = 1 | \tilde{Y}_{ijk} = 1) &+ \text{pr}(Y_{ijk} = 1, T_{ijk'}^{(\text{AT})} = 1 | \tilde{Y}_{ijk} = 1) \\ &- \text{pr}(Y_{ijk} = 1, T_{ijk}^{(\text{AT})} = 1, T_{ijk'}^{(\text{AT})} = 1 | \tilde{Y}_{ijk} = 1), \end{aligned}$$

and, in the [supplementary material](#) available at *Biostatistics* online, we derive each of these probabilities. We also show the pooling specificity

$$\text{PS}_{p:k} = 1 - \frac{\bar{S}_{p:k}^{(1)}}{\bar{\pi}_k} \left\{ \text{EFF}(\text{AT}) - \frac{\pi_k \text{PS}_{e:k}}{S_{e:k}^{(1)}} - \frac{2}{n} \right\},$$

where  $\bar{S}_{p:k}^{(1)} = 1 - S_{p:k}^{(1)}$ ,  $\bar{\pi}_k = 1 - \pi_k$ , and  $\pi_k$  is the marginal prevalence of the  $k$ th disease.

### 3.3. Adding a master array test

In array testing for a single disease, [Kim and others \(2007\)](#) and [Westreich and others \(2008\)](#) have demonstrated that a simple modification to the two-stage procedure can further reduce the expected number of tests per individual when the probability of disease is very small. The modification involves performing a preliminary test on all specimens in the array; i.e., a test on all  $n^2$  specimens in an  $n \times n$  array. If this preliminary test is negative, all individuals in the array are declared to be negative without further testing. Otherwise, one proceeds to test the rows and columns as in the two-stage version.

We adapt this three-stage algorithm for use with  $K = 2$  diseases, denoted herein by ATM. In the first stage, let  $M_k = 1$  if the master array tests positively for the  $k$ th disease,  $M_k = 0$  otherwise. If the master array tests positively for either disease; i.e., if  $M_1 + M_2 \geq 1$ , then two-stage AT is used. Mathematically,

we can express the collection who are tested individually as  $\mathcal{M}_+ = \{\mathcal{I}_{ij} : T_{ij1}^{(ATM)} + T_{ij2}^{(ATM)} \geq 1\}$ , where, for  $k = 1, 2$ ,

$$T_{ijk}^{(ATM)} = I(M_1 + M_2 \geq 1, R_{ik} = 1, C_{jk} = 1) + I\left(M_1 + M_2 \geq 1, R_{ik} = 1, \sum_{j=1}^n C_{jk} = 0\right) + I\left(M_1 + M_2 \geq 1, C_{jk} = 1, \sum_{i=1}^n R_{ik} = 0\right).$$

Therefore, the efficiency of ATM is given by

$$EFF(ATM) = \frac{1}{n^2} \left\{ 1 + 2n \text{pr}(M_1 + M_2 \geq 1) + n^2 \text{pr}(T_{ij1}^{(ATM)} + T_{ij2}^{(ATM)} \geq 1) \right\}.$$

In the [supplementary material](#) available at *Biostatistics* online, we derive  $EFF(ATM)$  in closed form as well as the classification accuracy probabilities  $PS_{e:k}$  and  $PS_{p:k}$  for ATM. These derivations require a slight modification of Assumption 3 (see Section 2) where now known values of  $S_{e:k}^{(n^2)}$  and  $S_{p:k}^{(n^2)}$  are elicited for the master array. The conditional independence assumption (Assumption 5) is also broadened to include the master array’s testing response.

#### 4. COMPARISONS

We compare our array-testing procedures to the hierarchical algorithms in [Tebbs and others \(2013\)](#) and [Hou and others \(2017\)](#). To examine low-prevalence diseases where pooling would be useful, we consider values of  $p_{00} \in \{0.90, 0.95, 0.97, 0.99\}$  and vary the remaining probabilities  $p_{10}$ ,  $p_{01}$ , and  $p_{11}$  in two ways. First, we select these probabilities so that the marginal disease probabilities  $\pi_1 = p_{10} + p_{11}$  and  $\pi_2 = p_{01} + p_{11}$  are equal. Second, we investigate cases where the marginal probabilities are unequal; specifically, cases where  $\pi_1$  is approximately 4–5 times larger than  $\pi_2$ . To incorporate the possibility of misclassification for each disease, we assume  $S_{e:k} = 0.95$  and  $S_{p:k} = 0.99$  when testing all pools (regardless of size) and all individuals. This might be reasonable when a multiplex assay can be calibrated to perform similarly on both pooled and individual specimens; see Section 5. All of our array calculations of efficiency and classification accuracy are exact, based on the derivations described in Section 3.

Because AT (ATM) is a two-stage (three-stage) procedure, our focus is on comparing (i) AT with the two-stage procedure in [Tebbs and others \(2013\)](#), denoted by H2, and (ii) ATM with the three-stage procedure in [Hou and others \(2017\)](#), denoted by H3. These comparisons are probably the most logical, as case identification algorithms using the same number of stages have similar levels of complexity with regard to implementation and similar turnaround times ([Westreich and others, 2008](#)). All comparisons are made by using the optimal versions of each algorithm in terms of efficiency. In other words, we identify and compare the array and hierarchical procedures that minimize the expected number of tests per individual. Note that we do invoke one constraint when selecting the optimal ATM algorithm; namely, we do not consider arrays larger than  $10 \times 10$ . This bounds the number of individuals in the master array test at 100, a constraint also used in [Kim and others \(2007\)](#) and [Kim and Hudgens \(2009\)](#) for single diseases out of concerns for dilution. Similar concerns can arise with multiplex assays; see Section 5.

Efficiency comparisons for the eight configurations of  $p_{00}$ ,  $p_{10}$ ,  $p_{01}$ , and  $p_{11}$  are shown in Table 1. Examining the two-stage designs, AT confers substantial gains in efficiency when compared with H2. For example, in Case 2 where the marginal disease probabilities are both 0.03, AT with  $11 \times 11$  arrays is 20.6% more efficient than the best two-stage hierarchical algorithm H2 (0.344 versus 0.433, respectively). This and the other efficiency gains in Table 1, which range from 9.1% to 41.1%, are practically significant for

Table 1. Efficiency of two- and three-stage algorithms with  $S_{e:k} = 0.95$  and  $S_{p:k} = 0.99$  for testing all pools (regardless of size) and individuals. H2 and H3 (hierarchical) algorithms are from [Tebbs and others \(2013\)](#) and [Hou and others \(2017\)](#), respectively. Pool sizes are chosen to minimize the expected number of tests per individual. The maximum allowable array size for ATM is  $10 \times 10$ . For Cases 1–4, the marginal disease probabilities  $\pi_1 = p_{10} + p_{11}$  and  $\pi_2 = p_{01} + p_{11}$  are equal. For Cases 5–8, the marginal disease probabilities are unequal

		Stages	Algorithm	Efficiency		Stages	Algorithm	Efficiency
Case 1	$p_{00} = 0.90$	2	H2(4 : 1)	0.594	Case 5	$p_{00} = 0.90$	H2(4 : 1)	0.591
	$p_{10} = 0.04$		AT(8 × 8)	0.530		$p_{10} = 0.08$	AT(8 × 8)	0.537
	$p_{01} = 0.04$	3	H3(9 : 3 : 1)	0.572		$p_{01} = 0.016$	H3(9 : 3 : 1)	0.564
	$p_{11} = 0.02$		ATM(8 × 8)	0.543		$p_{11} = 0.004$	ATM(8 × 8)	0.544
Case 2	$p_{00} = 0.95$	2	H2(5 : 1)	0.433	Case 6	$p_{00} = 0.95$	H2(5 : 1)	0.431
	$p_{10} = 0.02$		AT(11 × 11)	0.344		$p_{10} = 0.04$	AT(11 × 11)	0.352
	$p_{01} = 0.02$	3	H3(9 : 3 : 1)	0.371		$p_{01} = 0.008$	H3(9 : 3 : 1)	0.368
	$p_{11} = 0.01$		ATM(10 × 10)	0.354		$p_{11} = 0.002$	ATM(10 × 10)	0.356
Case 3	$p_{00} = 0.97$	2	H2(7 : 1)	0.345	Case 7	$p_{00} = 0.97$	H2(7 : 1)	0.342
	$p_{10} = 0.01$		AT(14 × 14)	0.258		$p_{10} = 0.025$	AT(15 × 15)	0.260
	$p_{01} = 0.01$	3	H3(16 : 4 : 1)	0.273		$p_{01} = 0.004$	H3(16 : 4 : 1)	0.268
	$p_{11} = 0.01$		ATM(10 × 10)	0.282		$p_{11} = 0.001$	ATM(10 × 10)	0.279
Case 4	$p_{00} = 0.99$	2	H2(11 : 1)	0.209	Case 8	$p_{00} = 0.99$	H2(11 : 1)	0.208
	$p_{10} = 0.004$		AT(29 × 29)	0.123		$p_{10} = 0.008$	AT(29 × 29)	0.128
	$p_{01} = 0.004$	3	H3(25 : 5 : 1)	0.135		$p_{01} = 0.0016$	H3(25 : 5 : 1)	0.134
	$p_{11} = 0.002$		ATM(5 × 5)	0.150		$p_{11} = 0.0004$	ATM(5 × 5)	0.150

high-volume laboratories that already use H2 for multiple diseases; as a two-stage procedure itself, AT is an attractive alternative to further reduce testing costs without requiring additional resources. Moving to the three-stage comparisons, ATM improves upon the best three-stage hierarchical algorithm H3 in the  $p_{00} = 0.90$  and  $p_{00} = 0.95$  cases, but not in the  $p_{00} = 0.97$  and  $p_{00} = 0.99$  cases; i.e., where one or both diseases are more rare. Note that our comparisons may penalize ATM slightly in some cases because we do not consider arrays larger than  $10 \times 10$  for ATM. Furthermore, it is interesting to note that in each of the eight configurations, the best AT procedure is more efficient than the best H3 procedure.

To complement the results in Table 1, we performed a simulation study to assess the variability in the number of tests per individual for the four algorithms H2, AT, H3, and ATM using the optimal configurations identified in Table 1. For each of the eight parameter configurations, we generated the true disease statuses of 100 000 individuals, assigned the individuals to master pools, and executed each algorithm while assuming  $S_{e:k} = 0.95$  and  $S_{p:k} = 0.99$  as before. This process was repeated  $B = 1000$  times for each parameter configuration. Figure 2 displays boxplots of the resulting 1000 values of the number of tests per individual for Cases 1–4 in Table 1; the same boxplots for Cases 5–8 are shown in the [supplementary material](#) available at *Biostatistics* online. In all eight cases, there are only minor differences in the variability in the number of tests per individual. Furthermore, among all four procedures, the empirical distributions described by the boxplots tend to favor AT as providing the smallest number of tests per individual.

Finally, any comparison of competing case identification algorithms should examine classification accuracy. In the [supplementary material](#) available at *Biostatistics* online, we provide values of  $PS_{e:k}$  and  $PS_{p:k}$  for each of the eight cases in Table 1. We also include the pooling positive and negative predictive






Fig. 2. Simulation study for Cases 1–4 in Table 1. Boxplots of the number of tests per individual using  $B = 1000$  Monte Carlo data sets. Array and hierarchical group sizes are the same as those in Table 1. The same figure for Cases 5–8 in Table 1 is in the [supplementary material](#) available at *Biostatistics* online.

values for each disease; i.e.,

$$PPV_k = \frac{\pi_k PS_{e:k}}{\pi_k PS_{e:k} + (1 - \pi_k)(1 - PS_{p:k})} \quad \text{and} \quad NPV_k = \frac{(1 - \pi_k) PS_{p:k}}{(1 - \pi_k) PS_{p:k} + \pi_k(1 - PS_{e:k})}.$$

For the  $k$ th disease,  $PPV_k$  ( $NPV_k$ ) gives the probability an individual is truly positive (negative) given that the algorithm has classified the individual positively (negatively). Our calculations show that all four algorithms increase specificity ( $PS_{p:k}$ ) when compared with individual testing and that their negative predictive values  $NPV_k$  are similar. Hierarchical algorithms are slightly preferred overall in terms of pooling sensitivity. On the other hand, AT can provide higher values of  $PPV_k$  when compared with H2, most notably when  $p_{00}$  is larger.

## 5. APPLICATION

Chlamydia (CT) and gonorrhea (NG) are two of the most common sexually transmitted diseases in the United States and elsewhere. In 2014, the Centers for Disease Control and Prevention (CDC) estimated that about 1.8 million new infections were reported in the United States (CDC, 2015). Untreated infections can lead to serious medical problems, including pelvic inflammatory disease, infertility, ectopic pregnancy, sterility, and an increased likelihood of acquiring or transmitting HIV (Papp and others, 2014; CDC, 2015). There is also a concern that certain strains of NG may soon become completely resistant to standard antibiotics used for treatment (Kirkcaldy and others, 2016). This has put new pressures on public health officials at statewide testing centers as they attempt to curtail the spread of both diseases.

Unfortunately, federal funds allocated to screen for CT/NG in the United States have declined in recent years, and this trend is expected to continue. The downward trend started in 2010 and coincided with the passage of the Affordable Care Act, which stipulated new requirements for private health insurance policies to cover CT/NG testing and other preventative services for young and “at-risk” women (JSI Research & Training Institute/Denver, 2013). This soon after led to the discontinuation of the largest nationally funded CT/NG screening program in the United States, the Infertility Prevention Project, which since 1988 had provided financial support to public health laboratories in all 50 states. Dissolving the IPP has reduced the annual CT/NG testing budgets of these laboratories, leaving officials overseeing screening programs to become increasingly concerned about testing costs.

Given the current funding environment, pooling specimens emerges as an excellent option for statewide testing centers to reduce the cost of testing. The largest public health laboratory in Iowa, the State Hygienic Laboratory (SHL) in Coralville, already uses group testing with a multiplex CT/NG assay to accomplish this. Each year, the SHL receives thousands of individual specimens from STD clinics and family planning centers located throughout the state. Upon arrival at the laboratory, specimens are first cross-classified according to sex (female/male) and type (swab/urine). This quadfurcation of specimens is done primarily for two reasons. First, commercially available CT/NG multiplex assays exhibit different accuracy levels for individuals in these four strata (Gaydos and others, 2003, 2010; Cheng and others, 2011). Second, the populations of individuals represented by the specimens received at the SHL are substantially different for females and males. Males are more likely to be tested only when they exhibit symptoms of infection (e.g., painful urination/ejaculation, etc.), whereas most females are tested annually as part of routine health examinations.

The Iowa SHL uses the two-stage hierarchical procedure (H2) described in Tebbs and others (2013) to test female swab specimens in pools of size 4. All specimens from the other three strata (female urine, male swab, and male urine) are tested individually. In the hope of reducing testing costs further, our colleagues at the SHL are interested in the following questions:

1. Can AT, a comparable two-stage procedure, reduce the number of tests needed to diagnose female swab specimens for CT/NG?
2. Should the SHL pool specimens in the other three strata? If so, how does AT compare to hierarchical algorithms?

Using historical data from the SHL, we perform a feasibility study to investigate both questions.

Table 2 summarizes the diagnoses of 33 811 Iowa residents during the 2013 calendar year. These diagnoses are cross-classified by sex and specimen type, and estimates of  $p_{00}$ ,  $p_{10}$ ,  $p_{01}$ , and  $p_{11}$  within each sex/specimen type stratum are provided. The SHL uses the Gen-Probe Aptima Combo 2 Assay (AC2A), a multiplex assay that utilizes nucleic acid amplification techniques to detect ribosomal RNA from CT and/or NG. The values of  $S_{e,k}$  and  $S_{p,k}$  provided in Table 2 are taken from Gen-Probe’s product literature for the AC2A. Specimens are carefully prepared by the lead technician at the SHL to ensure that testing

Table 2. Iowa SHL data summary. CT/NG diagnoses for 33,811 individuals during 2013, cross-classified by sex and specimen type. Stratum sample sizes  $N$  are shown. Estimates of  $p_{00}$ ,  $p_{10}$ ,  $p_{01}$ , and  $p_{11}$  are provided. The values of sensitivity and specificity are taken from the product literature for the Aptima Combo 2 Assay (1 = CT; 2 = NG). The algorithms shown in the last column minimize the expected number of tests per individual

Stratum	Count	CT/NG	Estimate	Sensitivity	Specificity	Algorithms
Female Swab ( $N = 20332$ )	18775	-/-	$\hat{p}_{00} = 0.923$	$S_{e:1} = 0.942$ $S_{e:2} = 0.992$	$S_{p:1} = 0.976$ $S_{p:2} = 0.987$	H2(4 : 1) AT(8 × 8) H3(9 : 3 : 1)
	1442	+/-	$\hat{p}_{10} = 0.071$			
	63	-/+	$\hat{p}_{01} = 0.003$			
	52	+/+	$\hat{p}_{11} = 0.003$			
Female Urine ( $N = 5998$ )	5438	-/-	$\hat{p}_{00} = 0.906$	$S_{e:1} = 0.947$ $S_{e:2} = 0.913$	$S_{p:1} = 0.989$ $S_{p:2} = 0.993$	H2(4 : 1) AT(7 × 7) H3(9 : 3 : 1)
	521	+/-	$\hat{p}_{10} = 0.087$			
	21	-/+	$\hat{p}_{01} = 0.004$			
	18	+/+	$\hat{p}_{11} = 0.003$			
Male Swab ( $N = 1298$ )	1050	-/-	$\hat{p}_{00} = 0.809$	$S_{e:1} = 0.959$ $S_{e:2} = 0.991$	$S_{p:1} = 0.975$ $S_{p:2} = 0.978$	H2(3 : 1) AT(6 × 6) H3(9 : 3 : 1)
	183	+/-	$\hat{p}_{10} = 0.141$			
	43	-/+	$\hat{p}_{01} = 0.033$			
	22	+/+	$\hat{p}_{11} = 0.017$			
Male Urine ( $N = 6183$ )	5137	-/-	$\hat{p}_{00} = 0.830$	$S_{e:1} = 0.979$ $S_{e:2} = 0.985$	$S_{p:1} = 0.985$ $S_{p:2} = 0.996$	H2(3 : 1) AT(5 × 5) H3(9 : 3 : 1)
	919	+/-	$\hat{p}_{10} = 0.149$			
	73	-/+	$\hat{p}_{01} = 0.012$			
	54	+/+	$\hat{p}_{11} = 0.009$			

error rates are the same for pooled specimens and individual specimens, so we perform our study under this assumption. The lab’s lead virologist estimates that each application of the AC2A costs the laboratory \$37 and requires 6 h to complete.

Our study is performed as follows. Using the 2013 estimates and common values of  $S_{e:k}$  and  $S_{p:k}$  for pools and individuals, we first determine the most efficient versions of H2, AT, and H3 for each sex/specimen type stratum while assuming the master pool size is no larger than 10; see Table 2. This constraint was invoked because the pooling literature for CT/NG has not examined using pools larger than this; for this same reason, we did not include ATM in this investigation. For each of the four strata, we then simulate individual CT/NG diagnoses to emulate what would have occurred had these optimal algorithms been used. For example, in the female/swab stratum, we simulate the true CT/NG statuses of  $N = 20\,332$  individuals based on the 2013 estimates, assign these individuals to optimally sized versions of H2, AT, and H3, and then perform each algorithm. This same strategy is then implemented in the other three sex/specimen type strata, and this is repeated  $B = 5000$  times in each stratum. We used individual testing for those individuals that remained when a complete master pool/array could not be formed. For example, in the female/swab stratum with  $N = 20\,332$  individuals, there were 5083 master pools created for H2(4 : 1), 317 master arrays created for AT(8 × 8), and 2259 master pools created for H3(9 : 3 : 1), admitting 0, 44, and 1 individual tests, respectively.

Table 3 shows the results. With the 5000 data sets created in each sex/specimen type stratum, we calculate the mean and standard deviation of the number of tests expended by H2, AT, and H3 to classify all individuals for CT and NG. We also report estimates of the four accuracy probabilities ( $PS_{e:k}$ ,  $PS_{p:k}$ ,  $PPV_k$ , and  $NPV_k$ ) in each stratum for each disease, which are calculated by comparing the true CT/NG statuses to the simulated diagnoses in each data set and then averaging across them. Boxplots showing the

Table 3. Iowa SHL feasibility study results. Estimated operating characteristics for optimal algorithms based on  $B = 5000$  data sets in each sex/specimen type stratum. The average (Mean) and standard deviation (SD) of the number of tests are provided. Stratum sample sizes  $N$  are shown. The estimated efficiency (EFF) is the mean number of tests divided by  $N$ . Accuracy probabilities ( $1 = CT$ ;  $2 = NG$ ) are estimated by averaging over the 5000 data sets

Stratum	Algorithm	Mean (SD)	EFF	PS <sub>e:1</sub>	PS <sub>e:2</sub>	PS <sub>p:1</sub>	PS <sub>p:2</sub>	PPV <sub>1</sub>	PPV <sub>2</sub>	NPV <sub>1</sub>	NPV <sub>2</sub>
Female Swab ( $N = 20332$ )	H2(4 : 1)	10907 (130)	0.536	0.891	0.989	0.994	0.996	0.927	0.620	0.991	1.000
	AT(8 × 8)	9930 (166)	0.488	0.844	0.989	0.996	0.997	0.938	0.662	0.988	1.000
	H3(9 : 3 : 1)	9815 (170)	0.483	0.844	0.986	0.996	0.997	0.950	0.698	0.988	1.000
Female Urine ( $N = 5998$ )	H2(4 : 1)	3429 (73)	0.572	0.899	0.876	0.997	0.998	0.969	0.735	0.990	0.999
	AT(7 × 7)	3253 (86)	0.542	0.856	0.890	0.998	0.998	0.976	0.779	0.986	0.999
	H3(9 : 3 : 1)	3223 (94)	0.537	0.856	0.851	0.998	0.998	0.978	0.786	0.986	0.999
Male Swab ( $N = 1298$ )	H2(3 : 1)	1058 (30)	0.815	0.928	0.987	0.990	0.990	0.947	0.839	0.987	0.999
	AT(6 × 6)	1044 (44)	0.804	0.895	0.984	0.990	0.990	0.946	0.842	0.980	0.999
	H3(9 : 3 : 1)	1110 (43)	0.855	0.906	0.985	0.991	0.990	0.948	0.844	0.983	0.999
Male Urine ( $N = 6183$ )	H2(3 : 1)	4726 (66)	0.764	0.960	0.979	0.995	0.998	0.973	0.926	0.993	1.000
	AT(5 × 5)	4796 (85)	0.776	0.942	0.980	0.996	0.999	0.978	0.936	0.989	1.000
	H3(9 : 3 : 1)	4942 (94)	0.799	0.944	0.977	0.995	0.998	0.974	0.928	0.990	1.000

distributions of the number of tests are provided in the [supplementary material](#) available at *Biostatistics* online. All operating characteristics in Table 3 are estimates calculated from our feasibility study. Exact values of the efficiency and accuracy probabilities for H2, AT, and H3 (based on the information in Table 2) are also provided in the [supplementary material](#) available at *Biostatistics* online. The estimates in Table 3 are very close to these exact values, although minor differences arise occasionally for AT because we used individual testing for remainder arrays.

We now return to the questions posed by our colleagues. For the first question, our investigation shows that switching from H2 to AT could be beneficial when screening female swab specimens for CT/NG. The estimated efficiency for AT is 0.488 (see Table 3), which represents a 9.0% reduction in the average number of tests per year when compared with H2 (EFF = 0.536). Assuming  $N = 20,322$  specimens are received per year, this translates to an average reduction of 977 tests and an annual savings of \$36 149. The performance of AT is also comparable to H3, which is even slightly more efficient (EFF = 0.483). AT and H3 provide about the same variability in the number of tests expended and similar levels of accuracy. Choosing between AT and H3 might involve a detailed examination of each algorithm's level of logistical complexity. For example, with each application of the AC2A taking 6 h, H3 could increase the turnaround time from 12 h (for AT) to 18 h, potentially delaying the laboratory in providing positive diagnoses by one working day. At the same time, the most efficient version of AT requires a larger number of specimens to pool ( $8 \times 8 = 64$ ) than H3, which may delay testing all together if not enough specimens are received. These logistical issues aside, the only reason to continue using H2 might be that it provides a slight improvement in pooling sensitivity for CT.

For the second question, it is difficult to argue that pooling would not be useful when testing female urine specimens for CT/NG. The estimated efficiency of H2 is 0.572, which would provide an annual cost savings of \$95 053 when compared with individual testing. AT and H3 can be even more efficient, reducing the average number of tests further by about 200 per year. Moving to the male strata, where the proportion of positives is larger, the benefits of pooling are obviously reduced but are probably still large enough to garner attention. For example, when screening male urine specimens for CT/NG, optimal versions of H2

and AT both reduce the average number of tests by about 1400 per year when compared with individual testing, which corresponds to over \$50 000 in annual savings. On the other hand, individual testing might be preferred for male swab specimens due to the high prevalence in this stratum and also because the SHL receives far fewer specimens of this type each year.

## 6. DISCUSSION

We have extended the utility of array testing to screening applications that use multiplex assays. For two diseases, we obtain closed-form expressions for the expected number of tests per individual and relevant classification accuracy probabilities. These expressions show that array testing can dramatically reduce the number of tests needed when compared with two-stage hierarchical algorithms and can compete well with hierarchical algorithms which use a larger number of stages. Our case study using CT/NG data in Iowa sheds light on questions posed by public-health officials and illustrates the cost-saving benefits of using array testing in practice.

On a recent visit to the SHL, our colleagues expressed concern about the future of CT/NG screening in the United States. This is due primarily to the fact that federal and state funds for screening are “plummeting” and the belief that CT/NG prevalence rates could rise as a result. It is our hope that the pooling algorithms described in this article and those in [Tebbs and others \(2013\)](#) and [Hou and others \(2017\)](#) will provide laboratories with viable options to reduce their testing costs for CT/NG screening purposes. To disseminate our work to potential stakeholders, we have created an R/Shiny application that performs efficiency and classification accuracy calculations for the algorithms in all three articles and determines the most efficient algorithm of each type. This resource should allow public health officials and lab technicians to quickly explore the potential benefits of CT/NG pooling and make informed decisions about which algorithm might be best to implement in their own laboratories.

We conclude with two remarks. First, an anonymous reviewer has pointed out that the population-level parameters  $p_{00}$ ,  $p_{10}$ ,  $p_{01}$ , and  $p_{11}$  are rarely known exactly, yet any evaluation of our algorithms in this article depends on them. Of course, estimates of disease prevalence can be obtained from previous periods of testing (e.g., the SHL has been testing Iowa residents for CT/NG in pools since 1999); however, even good estimates are still subject to uncertainty. One possible way to address this issue would be to perform efficiency and accuracy calculations for a range of disease prevalence values (and possibly assay accuracy probabilities too) and select the optimal design based on those identified in this range. Our R/Shiny application makes this approach feasible as all calculations in this article (for  $K = 2$  diseases) can be performed almost instantly for arrays of reasonable size. Second, it is easy to envision how array testing would work with a discriminating multiplex assay for three or more diseases. In fact, [Stramer and others \(2013\)](#) describe how “triplex” nucleic acid test assays for the detection of HIV, HBV, and HCV have been available since 2007 and summarize a feasibility study that evaluates a discriminating assay of this type with pooled samples from blood donors in the United States. Deriving closed-form expressions for the efficiency and classification accuracy probabilities for  $K \geq 3$  diseases with AT (or ATM) becomes nearly overwhelming even when  $K = 3$ ; however, our R/Shiny application will approximate these quantities by using simulation.

## 7. SOFTWARE

Software in the form of R code is available on GitHub (<https://github.com/harrindy/multiplex>).

## 8. SUPPLEMENTARY MATERIAL

Supplementary material is available online at <http://biostatistics.oxfordjournals.org>.

## ACKNOWLEDGMENTS

The authors thank the Editors, the Associate Editor, and two anonymous referees for their help in improving this article. They also thank Jeffrey Benfer, Dr Lucy DesJardin, and Kristofer Eveland at the State Hygienic Laboratory (University of Iowa) and Dr Elizabeth Torrone at the Centers for Disease Control and Prevention. *Conflict of Interest*: None declared.

## FUNDING

This research was supported by Grant R01 AI121351 from the National Institutes of Health.

## REFERENCES

- BUSCH, M., CAGLIOTI, S., ROBERTSON, E., MCAULEY, J., TOBLER, L., KAMEL, H., LINNEN, J., SHYAMALA, V., TOMASULO, P. AND KLEINMAN S. (2005). Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. *New England Journal of Medicine* **353**, 460–467.
- CENTERS FOR DISEASE CONTROL AND PREVENTION (2015). *Sexually Transmitted Disease Surveillance 2014*. Atlanta, GA: U.S. Department of Health and Human Services. [www.cdc.gov](http://www.cdc.gov). Accessed August 8, 2018.
- CHENG, A., QIAN, Q. AND KIRBY, J. (2011). Evaluation of the Abbott RealTime CT/NG assay in comparison to the Roche Cobas AmpliCor CT/NG Assay. *Journal of Clinical Microbiology* **49**, 1294–1300.
- DORFMAN, R. (1943). The detection of defective members of large populations. *Annals of Mathematical Statistics* **14**, 436–440.
- EDOUARD, S., PRUDENT, E., GAUTRET, P., MEMISH, Z. AND RAOULT, D. (2015). Cost-effective pooling of DNA from nasopharyngeal swab samples for large-scale detection of bacteria by real-time PCR. *Journal of Clinical Microbiology* **52**, 1002–1004.
- ELLINGTON, A., KULLO, I., BAILEY, K. AND KLEE, G. (2010). Antibody-based protein multiplex platforms: technical and operational challenges. *Clinical Chemistry* **56**, 186–193.
- GAYDOS, C., CARTWRIGHT, C., COLIANINNO, P., WELSCH, J., HOLDEN, J., HO, S., WEBB, E., ANDERSON, C., R., ZHANG, L., MILLER, T., LECKIE, G., ABRAYAYA, K. AND ROBINSON, J. (2010). Performance of the Abbott RealTime CT/NG for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Journal of Clinical Microbiology* **48**, 3236–3243.
- GAYDOS, C., QUINN, T., WILLIS, D., WEISSFELD, A., HOOK, E., MARTIN, D., FERRERO, D. AND SCHACHTER, J. (2003). Performance of the APTIMA combo 2 assay for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in female urine and endocervical swab specimens. *Journal of Clinical Microbiology* **41**, 304–309.
- HOU, P., TEBBS, J., BILDER, C. AND MCMAHAN, C. (2017). Hierarchical group testing for multiple infections. *Biometrics* **73**, 656–665.
- HUDGENS, M. AND KIM, H. (2011). Optimal configuration of a square array group testing algorithm. *Communications in Statistics: Theory and Methods* **40**, 436–448.
- JSI RESEARCH & TRAINING INSTITUTE, INC./DENVER (2013). The future of Infertility Prevention Project health impact assessment: Policy implications and recommendations in light of passage of the Patient Protection and Affordable Care Act, July 25, 2012. [www.nnptc.org](http://www.nnptc.org). Accessed August 8, 2018.
- KIM, H. AND HUDGENS, M. (2009). Three-dimensional array-based group testing algorithms. *Biometrics* **65**, 903–910.
- KIM, H., HUDGENS, M., DREYFUSS, J., WESTREICH, D. AND PILCHER, C. (2007). Comparison of group testing algorithms for case identification in the presence of testing error. *Biometrics* **63**, 1152–1163.
- KIRKCALDY, R., HARVEY, A., PAPP, J., and others (2016). *Neisseria gonorrhoeae* antimicrobial susceptibility surveillance: The gonococcal isolate surveillance project, 27 sites, United States, 2014. *Morbidity and Mortality Weekly Report* **65**. [www.cdc.gov](http://www.cdc.gov). Accessed August 8, 2018.

- LENDLE, S., HUDGENS, M. AND QAQISH, B. (2012). Group testing for case identification with correlated responses. *Biometrics* **68**, 532–540.
- LEWIS, J., LOCKARY, V. AND KOBIC, S. (2012). Cost savings and increased efficiency using a stratified specimen pooling strategy for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Sexually Transmitted Diseases* **39**, 46–48.
- MARTIN, E., SALARU, G., MOHAMMED, D., COOMBS, R., PAUL, S. AND CADOFF, E. (2013). Finding those at risk: acute HIV infection in Newark, NJ. *Journal of Clinical Virology* **58**, 24–28.
- MCMAHAN, C., TEBBS, J. AND BILDER, C. (2012). Two-dimensional informative array testing. *Biometrics* **68**, 793–804.
- MINE, H., EMURA, H., MIYAMOTO, M., TOMONO, T., MINEGISHI, K., MUROKAWA, H., YAMANAKA, R., YOSHIKAWA, A. AND NISHIOKA, K. (2003). High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. *Journal of Virological Methods* **112**, 145–151.
- O'BRIEN, S., YI, Q., FAN, W., SCALIA, V., FEARON, M. AND ALLAIN, J. (2012). Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. *Vox Sanguinis* **103**, 83–86.
- PAPP, J., SCHACHTER, J., GAYDOS, C. AND VAN DER POL, B. (2014). Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Morbidity and Mortality Weekly Report* **63**. [www.cdc.gov](http://www.cdc.gov). Accessed August 8, 2018.
- PHATARFOD, R. AND SUDBURY, A. (1994). The use of a square array scheme in blood testing. *Statistics in Medicine* **13**, 2337–2343.
- PILCHER, C., FISCUS, S., NGUYEN, T., FOUST, E., WOLF, L., WILLIAMS, D., ASHBY, R., O'DOWD, J., MCPHERSON, J., STALZER, B., HIGHTOW, L., MILLER, W., ERON, J., COHEN, M. AND LEONE, P. (2005). Detection of acute infections during HIV testing in North Carolina. *New England Journal of Medicine* **352**, 1873–1883.
- SAÁ, P., PROCTOR, M., FOSTER, G., KRYSZTOF, D., WINTON, C., LINNEN, J., GAO, K., BRODSKY, J., LIMBERGER, R., DODD, R. AND STRAMER, S. (2018). Investigational testing for Zika virus among US blood donors. *New England Journal of Medicine* **378**, 1778–1788.
- SCHMIDT, M., PICHL, L., JORK, C., HOURFAR, M., SCHOTTSTEDT, V., WAGNER, F., SEIFRIED, E., MULLER, T., BUX, J. AND SALDANHA, J. (2010). Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes. *Vox Sanguinis* **98**, 37–46.
- SEED, C., KIELY, P. AND KELLER, A. (2005). Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and human T lymphotropic virus. *Internal Medicine Journal* **35**, 592–598.
- SHERLOCK, M., ZELOTA, N. AND KLAUSNER, J. (2007). Routine detection of acute HIV infection through RNA pooling: Survey of current practice in the United States. *Sexually Transmitted Diseases* **34**, 314–316.
- STRAMER, S., KRYSZTOF, D., BRODSKY, J., FICKETT, T., REYNOLDS, B., DODD, R. AND KLEINMAN, S. (2013). Comparative analysis of triplex nucleic acid test assays in United States blood donors. *Transfusion* **53**, 2525–2537.
- TEBBS, J., MCMAHAN, C. AND BILDER, C. (2013). Two-stage hierarchical group testing for multiple infections with application to the Infertility Prevention Project. *Biometrics* **69**, 1064–1073.
- VANSTEELENDT, S., GOETGHEBEUR, E., THOMAS, I., MATHYS, E. AND VAN LOOCK, F. (2005). On the viral safety of plasma pools and plasma derivatives. *Journal of the Royal Statistical Society, Series A* **168**, 345–363.
- WANG, B., HAN, S., CHO, C., HAN, J., CHENG, Y., LEE, S., GALAPPATHY, G., THIMASARN, K., SOE, M., OO, H., KYAW, M. AND HAN, E. (2014). Comparison of microscopy, nested-PCR, and real-time-PCR assays using high throughput screening of pooled samples for diagnosis of malaria in asymptomatic carriers from areas of endemicity in Myanmar. *Journal of Clinical Microbiology* **52**, 1838–1845.
- WESTREICH, D., HUDGENS, M., FISCUS, S. AND PILCHER, C. (2008). Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. *Journal of Clinical Microbiology* **46**, 1785–1792.